Advancements in Prostate Cancer Imaging: The Evolution of PET Scans

Explore the transformative journey of prostate cancer imaging techniques, from conventional methods to cutting-edge PET scans like F-18 PSMA, and how FDA approvals have shaped their adoption.

EP: 1.An Overview of PSMA-PET Scans and Prostate Cancer Imaging

Now Viewing

EP: 2.Advancements in Prostate Cancer Imaging: The Evolution of PET Scans

EP: 3.Prostate Cancer Imaging: PSMA Agents and Radiotracer Options

EP: 4.Challenges and Progress in Advanced Imaging for Prostate Cancer

EP: 5.CMS Reimbursement Shift in Prostate Cancer: Streamlining Radiotracer Payments

EP: 6.Prostate Cancer Imaging and Care in 2023: Best Practices

EP: 7.Practical Guidance for Prostate Cancer Imaging: PSMA-PET Scans and Patient Selection

Related Videos

Related Content

Advertisement

January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

Related Content

Advertisement

January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.